MedPath

Study of dupilumab administration for refractory adulthood asthma

Not Applicable
Conditions
bronchial asthma
Registration Number
JPRN-UMIN000038873
Lead Sponsor
Sagamihara National Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. The sensitivity to multiple drugs 2. Women who is pregnancy or breast feeding 3. Patients who joins other clinical trial study 4. Patients judged unsuitable as subjects by doctor's judgment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in symptom score occured 1 to 4 months after administration of dupilumab
Secondary Outcome Measures
NameTimeMethod
Change in lung function test Change in inflammatory markers
© Copyright 2025. All Rights Reserved by MedPath